NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

MNKD

Mannkind Corp

Jul 01 • 11:18AM ET

3.67

Dollar change -0.07
Percentage change -1.86	%

Healthcare • Biotechnology • USA • NASD

Peers: NVO LLY SNY PFE GNFT TNDM DIOD DNLI ABT VRTX

| Held by: VTI IWM VXF XBI IWO IBB VTWO SCHA PBE KOMP

Scroll to Statements

Index	RUT	P/E	36.82	EPS (ttm)	0.10	Insider Own	3.12%	Shs Outstand	303.92M	Perf Week	-8.01%
Market Cap	1.12B	Forward P/E	15.42	EPS next Y	0.24	Insider Trans	-1.97%	Shs Float	294.46M	Perf Month	-11.55%
Enterprise Value	1.09B	PEG	0.79	EPS next Q	0.05	Inst Own	57.97%	Short Float	8.23%	Perf Quarter	-27.03%
Income	30.12M	P/S	3.75	EPS this Y	94.56%	Inst Trans	5.01%	Short Ratio	10.06	Perf Half Y	-46.73%
Sales	297.60M	P/B	-	EPS next Y	22.35%	ROA	6.76%	Short Interest	24.23M	Perf YTD	-42.91%
Book/sh	-0.19	P/C	6.15	EPS next 5Y	46.59%	ROE	-	52W High	7.63 -51.89%	Perf Year	-30.61%
Cash/sh	0.60	P/FCF	52.33	EPS past 3/5Y	- -	ROIC	65.20%	52W Low	3.63 1.12%	Perf 3Y	-5.40%
Dividend Est.	-	EV/EBITDA	12.36	Sales past 3/5Y	55.84% 35.27%	Gross Margin	74.62%	Volatility	4.94% 3.95%	Perf 5Y	97.34%
Dividend TTM	-	EV/Sales	3.66	EPS Y/Y TTM	236.33%	Oper. Margin	26.26%	ATR (14)	0.16	Perf 10Y	-87.64%
Dividend Ex-Date	-	Quick Ratio	2.11	Sales Y/Y TTM	32.50%	Profit Margin	10.12%	RSI (14)	35.17	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.36	EPS Q/Q	25.38%	SMA20	-6.93%	Beta	0.96	Target Price	9.43
Payout	0.00%	Debt/Eq	-	Sales Q/Q	18.25%	SMA50	-14.85%	Rel Volume	1.23	Prev Close	3.74
Employees	407	LT Debt/Eq	-	Earnings	May 08 BMO	SMA200	-34.78%	Avg Volume	2.41M	Price	3.67
IPO	Jul 28, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.85% 3.07%	Trades		Volume	927,846	Change	-1.86%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-25	Initiated	Mizuho	Outperform	$12
Feb-10-25	Initiated	Wedbush	Outperform	$11
Dec-20-24	Initiated	Wells Fargo	Overweight	$9
Dec-19-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$7 → $10
Sep-09-24	Resumed	Leerink Partners	Outperform	$7 → $8
Jun-13-24	Initiated	Rodman & Renshaw	Buy	$8
Oct-10-23	Initiated	Wedbush	Outperform	$10
May-14-21	Initiated	RBC Capital Mkts	Sector Perform	$5
Dec-24-19	Initiated	Oppenheimer	Outperform	$2.50
Oct-25-19	Initiated	Cantor Fitzgerald	Overweight	$3
May-14-19	Initiated	BTIG Research	Buy	$3
Mar-04-19	Initiated	SVB Leerink	Outperform	$3
Feb-22-19	Initiated	SVB Leerink	Outperform	$3
Feb-28-18	Downgrade	Maxim Group	Hold → Sell	$1
Nov-01-17	Downgrade	Maxim Group	Buy → Hold
Oct-10-17	Initiated	H.C. Wainwright	Buy	$7
Oct-06-17	Reiterated	Maxim Group	Buy	$4 → $7
Aug-11-17	Initiated	Maxim Group	Buy	$4
May-10-16	Reiterated	RBC Capital Mkts	Underperform	$0.15 → $0.20
May-10-16	Reiterated	Piper Jaffray	Underweight	$0.05 → $0.10

Show Previous Ratings

Jun-25-25 09:28AM	Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-24-25 03:52PM	Leerink Partners Slashes MannKind Corporation's (MNKD) Price Target to $7, Keeps a Buy Rating (Insider Monkey) +5.14%
Jun-23-25 12:16PM	MannKind (MNKD) Presents Pediatric Insulin Trial Data (Insider Monkey)
Jun-09-25 04:05PM	MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23 (GlobeNewswire) -10.30%
May-27-25 09:15AM	INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29 (GlobeNewswire)
04:05PM	Loading…
May-13-25 04:05PM	MannKind to Present at Upcoming Investor Conferences (GlobeNewswire)
May-09-25 10:31AM	MannKind Corporation (MNKD): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey)
May-08-25 09:25AM	MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates (Zacks)
08:21AM	MannKind: Q1 Earnings Snapshot (Associated Press Finance)
08:05AM	MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-07-25 12:32PM	MannKind Q1 2025 Earnings Preview (Seeking Alpha)
10:12AM	MannKind Corp (MNKD) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-05-25 04:06PM	Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month (Seeking Alpha)
May-01-25 04:05PM	MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025 (GlobeNewswire)
Apr-18-25 10:00AM	Is MannKind Corporation (MNKD) the Best Quality Penny Stock to Buy According to Hedge Funds? (READY TO EDIT2) (Insider Monkey)
11:17AM	Loading…
Apr-16-25 11:17AM	Is MannKind Corp. (NASDAQ:MNKD) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Apr-07-25 12:30PM	MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options (GlobeNewswire)
Mar-10-25 06:05AM	MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza at the ATTD Conference, March 19-22 (GlobeNewswire)
Feb-27-25 02:19AM	MannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
12:30AM	MannKind (MNKD) Q4 2024 Earnings Call Transcript (Motley Fool)
Feb-26-25 07:30PM	Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics (Zacks)
06:15PM	MannKind (MNKD) Q4 Earnings Meet Estimates (Zacks)
05:08PM	MannKind: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-25-25 10:30AM	MannKind Corp (MNKD) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-24-25 09:16AM	Unveiling MannKind (MNKD) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Feb-19-25 04:05PM	MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025 (GlobeNewswire)
Feb-06-25 04:05PM	MannKind to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-06-25 04:30PM	MannKind Expands Executive Leadership Team (GlobeNewswire)
08:47AM	Heres Why MannKind Corporation (NASDAQ:MNKD) Is Among the Best Diabetes Stocks to Buy Under $10 (Insider Monkey)
07:00AM	Loading…
Dec-18-24 07:00AM	MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash (GlobeNewswire)
Dec-16-24 06:05AM	MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza) (GlobeNewswire)
Dec-11-24 06:00AM	CDSCO Approves Afrezza (insulin human) Inhalation Powder in India (GlobeNewswire)
Nov-08-24 01:26PM	Q3 2024 MannKind Corp Earnings Call (Thomson Reuters StreetEvents)
02:28AM	MannKind Corp (MNKD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Nov-07-24 11:15PM	MannKind (MNKD) Q3 2024 Earnings Call Transcript (Motley Fool)
07:00PM	MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:40PM	MannKind (MNKD) Matches Q3 Earnings Estimates (Zacks)
04:34PM	MannKind: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-24 07:17AM	MannKind Corp (MNKD) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-05-24 04:15PM	MannKind to Present at 2024 UBS Healthcare Conference (GlobeNewswire)
Nov-04-24 06:05AM	MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases (GlobeNewswire)
Nov-01-24 09:15AM	MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run? (Zacks)
Oct-31-24 04:05PM	MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024 (GlobeNewswire)
Oct-30-24 09:00PM	First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease (GlobeNewswire)
Oct-09-24 05:13PM	MannKind Corp (MNKD) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Pipeline ... (GuruFocus.com)
Oct-07-24 12:10PM	Why MannKind (MNKD) Could Beat Earnings Estimates Again (Zacks)
Oct-04-24 09:35AM	MannKind (MNKD) Just Overtook the 20-Day Moving Average (Zacks)
Sep-30-24 08:01AM	Lytham Partners Announces KOL Panels and Participating Companies for its Fall 2024 Investor Conference (Newsfile)
06:00AM	More Adults With Type 1 Diabetes Achieved A1C Goal ( (GlobeNewswire)
Sep-21-24 02:47AM	MannKind Corporation (MNKD): Short Seller Sentiment is Bearish (Insider Monkey)
Sep-18-24 06:15AM	MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease (GlobeNewswire)
Sep-15-24 07:21PM	MannKind Corporation (MNKD): Short Seller Sentiment is Bearish on This Stock (Insider Monkey)
Sep-10-24 04:30PM	MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-05-24 01:33AM	Insider Sale: Chief People & Workpl Officer Stuart Tross Sells 25,000 Shares of MannKind ... (GuruFocus.com)
Aug-31-24 01:42AM	Insider Sale: Chief People & Workpl Officer Stuart Tross Sells 80,000 Shares of MannKind ... (GuruFocus.com)
Aug-27-24 04:30PM	MannKind to Present at Upcoming Conferences (GlobeNewswire) +9.67%
Aug-14-24 08:00AM	Kent Kresa to Retire from MannKind's Board of Directors; Steven B. Binder to be Appointed to the Board (GlobeNewswire)
Aug-09-24 09:40AM	Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-07-24 04:45PM	MannKind (MNKD) Q2 2024 Earnings Call Transcript (Motley Fool)
09:30AM	MannKind (MNKD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:10AM	MannKind (MNKD) Q2 Earnings and Revenues Surpass Estimates (Zacks)
08:08AM	MannKind: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update (GlobeNewswire)
Jul-31-24 06:30AM	MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease (GlobeNewswire)
Jul-30-24 04:30PM	MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024 (GlobeNewswire)
Jul-16-24 12:00PM	All You Need to Know About MannKind (MNKD) Rating Upgrade to Buy (Zacks)
09:40AM	Is MannKind (MNKD) Outperforming Other Medical Stocks This Year? (Zacks)
09:15AM	MannKind Corporation (MNKD) Hit a 52 Week High, Can the Run Continue? (Zacks)
Jun-22-24 08:00AM	INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
Jun-05-24 06:45AM	Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
May-29-24 08:45AM	Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation (PR Newswire)
08:45AM	MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix (GlobeNewswire)
May-13-24 12:00PM	MannKind (MNKD) Upgraded to Strong Buy: Here's Why (Zacks)
May-10-24 03:01AM	MannKind Corp (MNKD) Q1 2024 Earnings Call Transcript Highlights: A Quarter of Robust Growth ... (GuruFocus.com)
May-09-24 01:46PM	Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:47AM	MannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:15AM	MannKind (MNKD) Q1 2024 Earnings Call Transcript (Motley Fool)
May-08-24 07:30PM	Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics (Zacks)
07:10PM	MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates (Zacks)
06:07PM	MannKind: Q1 Earnings Snapshot (Associated Press Finance)
04:18PM	MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update (GlobeNewswire)
May-06-24 06:38AM	MannKind Receives FDA Fast Track Designation for its Potential Lung Disease Treatment (MT Newswires)
06:05AM	MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease (GlobeNewswire)
May-01-24 04:00PM	MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024 (GlobeNewswire) +5.60%
Apr-30-24 06:05AM	MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases (GlobeNewswire)
Apr-29-24 11:17AM	MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment (MT Newswires)
06:05AM	MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease (GlobeNewswire)
Apr-03-24 06:00AM	MannKind Repays Certain Debt Obligations (GlobeNewswire)
Mar-26-24 04:05PM	MannKind Announces CFO Transition (GlobeNewswire) -5.70%
Mar-25-24 11:45AM	Jim Cramer Says You Should Avoid These 11 Stocks (Insider Monkey)
Mar-11-24 06:05AM	INHALE-3 Study's Initial Meal Challenge Results Comparing Afrezza Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps (GlobeNewswire) -12.52%
Mar-05-24 06:05AM	MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8 (GlobeNewswire)
Mar-04-24 01:01PM	MannKind Corporation Announces Participation at Upcoming Conferences (GlobeNewswire)
Feb-28-24 09:30AM	MannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:11AM	Q4 2023 MannKind Corp Earnings Call (Thomson Reuters StreetEvents)
01:00AM	MannKind (MNKD) Q4 2023 Earnings Call Transcript (Motley Fool)
Feb-27-24 06:00PM	Here's What Key Metrics Tell Us About MannKind (MNKD) Q4 Earnings (Zacks) +5.59%
05:35PM	MannKind (MNKD) Q4 Earnings and Revenues Surpass Estimates (Zacks)

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Binder Steven B.	Director	Jun 10 '25	Sale	4.00	64,085	256,340	925,258	Jun 10 08:07 PM
STEVEN B BINDER	Director	Jun 10 '25	Proposed Sale	4.00	64,085	256,430		Jun 10 04:02 PM
Binder Steven B.	Director	May 20 '25	Sale	4.40	12,078	53,143	989,343	May 20 09:45 PM
Thomson David	EVP Genl Counsel & Secretary	May 20 '25	Sale	4.41	2,345	10,341	879,546	May 20 09:44 PM
DAVID THOMSON	Officer	May 20 '25	Proposed Sale	4.41	2,345	10,334		May 20 04:14 PM
STEVEN B BINDER	Director	May 20 '25	Proposed Sale	4.40	12,078	53,184		May 20 04:03 PM
Thomson David	EVP Genl Counsel & Secretary	May 13 '25	Sale	4.68	32,179	150,598	772,427	May 15 09:37 PM
Binder Steven B.	Director	May 13 '25	Sale	4.69	80,144	375,875	1,006,611	May 15 09:35 PM
STEVEN B BINDER	Director	May 13 '25	Proposed Sale	4.69	80,144	375,499		May 13 04:03 PM
DAVID THOMSON	Officer	May 13 '25	Proposed Sale	4.68	32,179	150,717		May 13 04:02 PM
Binder Steven B.	Director	Nov 22 '24	Option Exercise	1.47	67,536	99,278	1,142,562	Nov 25 09:30 PM
Binder Steven B.	Director	Nov 22 '24	Sale	6.89	67,536	465,323	1,075,026	Nov 25 09:30 PM
STEVEN B BINDER	Director	Nov 22 '24	Proposed Sale	6.89	67,536	465,397		Nov 22 04:08 PM
Binder Steven B.	Director	Nov 15 '24	Option Exercise	1.47	67,539	99,282	1,142,565	Nov 19 09:30 PM
Binder Steven B.	Director	Nov 15 '24	Sale	6.76	67,539	456,564	1,075,026	Nov 19 09:30 PM
STEVEN B BINDER	Officer	Nov 15 '24	Proposed Sale	6.76	67,539	456,793		Nov 15 04:01 PM
Tross Stuart A	Chief People & Workpl Officer	Nov 06 '24	Sale	7.34	55,000	403,700	967,191	Nov 08 09:30 PM
STUART A TROSS	Officer	Nov 06 '24	Proposed Sale	7.34	55,000	403,700		Nov 06 04:04 PM
Tross Stuart A	Chief People & Workpl Officer	Sep 03 '24	Sale	6.26	25,000	156,500	1,022,191	Sep 04 09:11 PM
STUART A TROSS	Officer	Sep 03 '24	Proposed Sale	6.26	25,000	156,380		Sep 03 04:25 PM
Tross Stuart A	Chief People & Workpl Officer	Aug 30 '24	Sale	6.33	80,000	506,050	1,047,191	Aug 30 09:00 PM
STUART A TROSS	Officer	Aug 30 '24	Proposed Sale	6.33	80,000	506,043		Aug 30 04:35 PM
Castagna Michael	Chief Executive Officer	Aug 29 '24	Sale	6.30	85,106	536,168	2,294,836	Aug 29 09:00 PM
Binder Steven B.	EVP Special Projects	Aug 29 '24	Sale	5.94	5,055	30,027	1,075,026	Aug 29 09:00 PM
Thomson David	EVP Genl Counsel & Secretary	Aug 29 '24	Sale	5.94	5,553	32,985	829,843	Aug 29 09:00 PM
Castagna Michael	Officer	Aug 29 '24	Proposed Sale	6.30	85,106	536,071		Aug 29 05:23 PM
DAVID THOMSON	Officer	Aug 29 '24	Proposed Sale	5.94	5,553	32,988		Aug 29 04:15 PM
STEVEN B BINDER	Officer	Aug 29 '24	Proposed Sale	5.94	5,055	30,031		Aug 29 04:15 PM
Binder Steven B.	EVP Special Projects	Jul 16 '24	Sale	5.93	2,836	16,817	1,100,860	Jul 17 07:49 PM
Thomson David	EVP Genl Counsel & Secretary	Jul 16 '24	Sale	5.93	3,115	18,472	857,885	Jul 17 07:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MNKD

Mannkind Corp

Upgrade your FINVIZ experience